The global market for cancer profiling technologies reached $26.1 billion in 2012. This market is expected to grow to nearly $30.1 billion in 2013 and $54.8 billion in 2018, a compound annual growth rate (CAGR) of 12.8% over the five-year period, 2013 to 2018.
This report provides:
-An overview of the global market for cancer profiling and biomarker studies
-Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
-Discussion of products in this market, cancer markets in newly emerging tools, diagnostics and therapeutics, and their impacts on the market
-Examination of evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, which are integral to deciphering the molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers
-Identifications of important cancer profiling techniques, market share by type of products on the market and market share by company, as well as types of cancers and biomarkers
-Coverage of epigenetic, methylation, and miRNA products in development, products in clinical trials, and currently marketed and clinical-stage development products
-Comprehensive company profiles of key players in the market.